GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (LTS:0JAV) » Definitions » Cyclically Adjusted Price-to-FCF

Insmed (LTS:0JAV) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Insmed Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insmed Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Insmed's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Cyclically Adjusted Price-to-FCF Chart

Insmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insmed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Insmed's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Insmed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted Price-to-FCF falls into.


;
;

Insmed Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Insmed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Insmed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.505/134.9266*134.9266
=-1.505

Current CPI (Mar. 2025) = 134.9266.

Insmed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.414 100.684 -0.555
201509 -0.403 100.392 -0.542
201512 -0.452 99.792 -0.611
201603 -0.487 100.470 -0.654
201606 -0.481 101.688 -0.638
201609 -0.522 101.861 -0.691
201612 -0.948 101.863 -1.256
201703 -0.602 102.862 -0.790
201706 -0.590 103.349 -0.770
201709 -0.592 104.136 -0.767
201712 -0.651 104.011 -0.844
201803 -0.950 105.290 -1.217
201806 -0.752 106.317 -0.954
201809 -0.874 106.507 -1.107
201812 -0.972 105.998 -1.237
201903 -1.004 107.251 -1.263
201906 -1.108 108.070 -1.383
201909 -0.750 108.329 -0.934
201912 -0.642 108.420 -0.799
202003 -0.675 108.902 -0.836
202006 -0.392 108.767 -0.486
202009 -0.585 109.815 -0.719
202012 -0.667 109.897 -0.819
202103 -1.256 111.754 -1.516
202106 -0.720 114.631 -0.847
202109 -0.657 115.734 -0.766
202112 -0.719 117.630 -0.825
202203 -0.899 121.301 -1.000
202206 -0.880 125.017 -0.950
202209 -0.748 125.227 -0.806
202212 -0.812 125.222 -0.875
202303 -1.098 127.348 -1.163
202306 -0.928 128.729 -0.973
202309 -0.974 129.860 -1.012
202312 -0.918 129.419 -0.957
202403 -1.271 131.776 -1.301
202406 -0.839 132.554 -0.854
202409 -1.063 133.029 -1.078
202412 -1.132 133.157 -1.147
202503 -1.505 134.927 -1.505

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insmed  (LTS:0JAV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Insmed Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Insmed's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Industry
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines